Fabry disease is a rare genetic lysosomal storage disorder in which the body lacks sufficient amounts of an enzyme that breaks down fats. The companies requested to approve the dosing regimen of 2 ...

-- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA -- -- Announces $8 Million Convertible Preferred Stock Financing with Park West and MSD Partners-- SPARTA, New Jersey, March 13, 2020 ...

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

-- Received FDA approval of sNDAs for both VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsule -- -- U.S. commercial launch of VAZALORE planned for third quarter 2021 -- -- ...

Protalix BioTherapeutics Inc. Annual cash flow by MarketWatch. View PLX net cash flow, operating cash flow, operating expenses and cash dividends.

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get ...